BR0312169A - Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinação - Google Patents
Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinaçãoInfo
- Publication number
- BR0312169A BR0312169A BR0312169-0A BR0312169A BR0312169A BR 0312169 A BR0312169 A BR 0312169A BR 0312169 A BR0312169 A BR 0312169A BR 0312169 A BR0312169 A BR 0312169A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- pathological condition
- treating
- reduction
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000001575 pathological effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title 1
- 230000008485 antagonism Effects 0.000 title 1
- 239000013066 combination product Substances 0.000 title 1
- 229940127555 combination product Drugs 0.000 title 1
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 abstract 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 abstract 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 abstract 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200201439A ES2203327B1 (es) | 2002-06-21 | 2002-06-21 | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| PCT/EP2003/006472 WO2004000840A2 (en) | 2002-06-21 | 2003-06-18 | Quinuclidine derivatives and pharmaceutical compositions containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0312169A true BR0312169A (pt) | 2005-03-29 |
Family
ID=29797397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0312169-0A BR0312169A (pt) | 2002-06-21 | 2003-06-18 | Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinação |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US7435742B2 (https=) |
| EP (1) | EP1515968A2 (https=) |
| JP (1) | JP2005533799A (https=) |
| CN (1) | CN100363363C (https=) |
| AR (1) | AR040275A1 (https=) |
| AU (1) | AU2003279384A1 (https=) |
| BR (1) | BR0312169A (https=) |
| CA (1) | CA2490082A1 (https=) |
| EC (1) | ECSP045484A (https=) |
| ES (1) | ES2203327B1 (https=) |
| IL (1) | IL165775A0 (https=) |
| MX (1) | MXPA04012272A (https=) |
| NO (1) | NO20050217L (https=) |
| NZ (1) | NZ537252A (https=) |
| PE (1) | PE20040579A1 (https=) |
| RU (1) | RU2321588C2 (https=) |
| TW (1) | TW200401776A (https=) |
| UA (1) | UA85541C2 (https=) |
| UY (1) | UY27850A1 (https=) |
| WO (1) | WO2004000840A2 (https=) |
| ZA (1) | ZA200410211B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4445704B2 (ja) | 2000-12-22 | 2010-04-07 | アルミラル・ソシエダッド・アノニマ | キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用 |
| ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| AU2005235419B2 (en) * | 2004-04-22 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations containing benzoxazine for treating respiratory diseases |
| JP2008505118A (ja) * | 2004-06-30 | 2008-02-21 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
| ES2246170B1 (es) * | 2004-07-29 | 2007-04-01 | Almirall Prodesfarma, S.A. | Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| CN101208316B (zh) | 2005-08-15 | 2012-05-09 | 贝林格尔·英格海姆国际有限公司 | 制备β-模拟物的方法 |
| DE102006028286A1 (de) * | 2006-06-20 | 2007-12-27 | Wirsich, Konrad, Dipl.-Ing. (FH) | Drehmoment- und rutschfest verbundene aus zwei Teilen bestehende Schaltzahnräder |
| EP1882691A1 (en) * | 2006-07-26 | 2008-01-30 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine derivatives as M3 antagonists |
| KR20090107567A (ko) * | 2007-02-09 | 2009-10-13 | 아스텔라스세이야쿠 가부시키가이샤 | 아자 가교환 화합물 |
| ES2554646T3 (es) * | 2007-02-23 | 2015-12-22 | Theravance Biopharma R&D Ip, Llc | Compuestos de difenilmetilo de amonio cuaternario, de utilidad como antagonistas de receptores muscarínicos |
| EP2065385A1 (en) | 2007-11-28 | 2009-06-03 | Laboratorios SALVAT, S.A. | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester |
| EP2080507A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical formulations comprising an anticholinergic drug |
| US8742131B2 (en) * | 2010-01-28 | 2014-06-03 | Theron Pharmaceuticals, Inc. | 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof |
| AU2012231275A1 (en) * | 2011-03-18 | 2013-10-17 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| EP2631674A1 (de) * | 2012-02-23 | 2013-08-28 | ELMOS Semiconductor AG | Verfahren und Sensorsystem zur Vermessung der Eigenschaften einer Übertragungsstrecke eines Messsystems zwischen Sender und Empfänger |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| EP3023424B1 (en) * | 2013-07-13 | 2019-02-27 | Beijing Shuobai Pharmaceutical Co., Ltd. | Quinine compounds, and optical isomers, preparation method and medical use thereof |
| US10570127B1 (en) | 2018-11-05 | 2020-02-25 | Renexxion, Llc | Material and methods for the treatment of gastro-intestinal disorders |
| CN114040762A (zh) | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
| TW202142236A (zh) | 2020-02-03 | 2021-11-16 | 美商健臻公司 | 用於治療與溶體儲積症相關的神經症狀之方法 |
| US12527775B2 (en) | 2020-03-26 | 2026-01-20 | Shionogi & Co., Ltd. | Heteroaromatic derivatives having serotonin receptor binding activity |
| KR20230043024A (ko) | 2020-07-24 | 2023-03-30 | 젠자임 코포레이션 | 벤글루스타트를 포함하는 제약 조성물 |
| JP7741820B2 (ja) * | 2020-12-28 | 2025-09-18 | 塩野義製薬株式会社 | セロトニン受容体結合活性を有する環状アミン誘導体 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2762796A (en) | 1956-09-11 | Iminodibenzyl derivative | ||
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| GB1246606A (en) | 1969-04-28 | 1971-09-15 | Starogardzkie Zakl Farma | Dibenzo-azepine derivatives |
| GB8825505D0 (en) * | 1988-11-01 | 1988-12-07 | Pfizer Ltd | Therapeutic agents |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| GB9201751D0 (en) | 1992-01-28 | 1992-03-11 | Smithkline Beecham Plc | Compounds |
| GB9202443D0 (en) | 1992-02-05 | 1992-03-18 | Fujisawa Pharmaceutical Co | A novel substituted-acetamide compound and a process for the preparation thereof |
| WO1995006635A1 (en) * | 1993-09-02 | 1995-03-09 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| WO1995021820A1 (en) * | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
| NO2005012I1 (no) * | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| ATE205490T1 (de) | 1995-10-13 | 2001-09-15 | Banyu Pharma Co Ltd | Substituierte heteroaromatische derivate |
| AUPN862996A0 (en) | 1996-03-13 | 1996-04-04 | Fujisawa Pharmaceutical Co., Ltd. | A novel substituted-acetamide compound |
| PE92198A1 (es) | 1996-08-01 | 1999-01-09 | Banyu Pharma Co Ltd | Derivados de 1,4-piperidina disustituida que contienen fluor |
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CZ294251B6 (cs) | 2000-06-27 | 2004-11-10 | Laboratorios S. A. L. V. A. T., S. A. | Karbamáty a jejich použití pro výrobu farmaceutického prostředku |
| JP4445704B2 (ja) | 2000-12-22 | 2010-04-07 | アルミラル・ソシエダッド・アノニマ | キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用 |
| IL156558A0 (en) | 2000-12-28 | 2004-01-04 | Almirall Prodesfarma Ag | Novel quinuclidine derivatives and medicinal compositions containing the same |
| EP1461336B1 (en) | 2001-12-20 | 2013-05-22 | CHIESI FARMACEUTICI S.p.A. | 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists |
| ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
-
2002
- 2002-06-21 ES ES200201439A patent/ES2203327B1/es not_active Expired - Fee Related
-
2003
- 2003-06-16 UY UY27850A patent/UY27850A1/es not_active Application Discontinuation
- 2003-06-18 WO PCT/EP2003/006472 patent/WO2004000840A2/en not_active Ceased
- 2003-06-18 RU RU2005101409/04A patent/RU2321588C2/ru not_active IP Right Cessation
- 2003-06-18 US US10/518,496 patent/US7435742B2/en not_active Expired - Fee Related
- 2003-06-18 MX MXPA04012272A patent/MXPA04012272A/es not_active Application Discontinuation
- 2003-06-18 UA UAA200500504A patent/UA85541C2/ru unknown
- 2003-06-18 AU AU2003279384A patent/AU2003279384A1/en not_active Abandoned
- 2003-06-18 CA CA002490082A patent/CA2490082A1/en not_active Abandoned
- 2003-06-18 JP JP2004514785A patent/JP2005533799A/ja active Pending
- 2003-06-18 PE PE2003000615A patent/PE20040579A1/es not_active Application Discontinuation
- 2003-06-18 BR BR0312169-0A patent/BR0312169A/pt not_active IP Right Cessation
- 2003-06-18 NZ NZ537252A patent/NZ537252A/en unknown
- 2003-06-18 CN CNB038193272A patent/CN100363363C/zh not_active Expired - Fee Related
- 2003-06-18 EP EP03740284A patent/EP1515968A2/en not_active Withdrawn
- 2003-06-19 AR ARP030102175A patent/AR040275A1/es unknown
- 2003-06-20 TW TW092116832A patent/TW200401776A/zh unknown
-
2004
- 2004-12-10 EC EC2004005484A patent/ECSP045484A/es unknown
- 2004-12-15 IL IL16577504A patent/IL165775A0/xx unknown
- 2004-12-17 ZA ZA200410211A patent/ZA200410211B/xx unknown
-
2005
- 2005-01-13 NO NO20050217A patent/NO20050217L/no not_active Application Discontinuation
-
2008
- 2008-09-05 US US12/205,315 patent/US20090005412A1/en not_active Abandoned
- 2008-09-05 US US12/205,334 patent/US20090054480A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PE20040579A1 (es) | 2004-09-08 |
| ZA200410211B (en) | 2005-09-06 |
| EP1515968A2 (en) | 2005-03-23 |
| ECSP045484A (es) | 2005-01-28 |
| AR040275A1 (es) | 2005-03-23 |
| MXPA04012272A (es) | 2005-04-08 |
| US20060094751A1 (en) | 2006-05-04 |
| US20090054480A1 (en) | 2009-02-26 |
| UY27850A1 (es) | 2003-11-28 |
| JP2005533799A (ja) | 2005-11-10 |
| CA2490082A1 (en) | 2003-12-31 |
| CN100363363C (zh) | 2008-01-23 |
| TW200401776A (en) | 2004-02-01 |
| AU2003279384A1 (en) | 2004-01-06 |
| NZ537252A (en) | 2006-07-28 |
| WO2004000840A3 (en) | 2004-02-19 |
| UA85541C2 (ru) | 2009-02-10 |
| WO2004000840A2 (en) | 2003-12-31 |
| IL165775A0 (en) | 2006-01-15 |
| US7435742B2 (en) | 2008-10-14 |
| CN1675206A (zh) | 2005-09-28 |
| NO20050217L (no) | 2005-03-18 |
| US20090005412A1 (en) | 2009-01-01 |
| RU2005101409A (ru) | 2005-11-20 |
| RU2321588C2 (ru) | 2008-04-10 |
| ES2203327A1 (es) | 2004-04-01 |
| ES2203327B1 (es) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312169A (pt) | Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinação | |
| BRPI0417820A (pt) | heterociclos azabicìclicos como moduladores de receptor canabinóide | |
| BRPI0509298A (pt) | composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto | |
| CY1109787T1 (el) | Ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις | |
| BRPI0821266B8 (pt) | Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica | |
| BRPI0417771A (pt) | heterociclos azabicìclicos como moduladores de receptor canabinóides | |
| BR0009320A (pt) | Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete | |
| BR0309167A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação | |
| CY1110922T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| IL184932A0 (en) | Glucagon receptor antagonists, preperation and therapeutic uses | |
| BRPI0519262A2 (pt) | derivados de pirazol fundidos e mÉtodos de tratamento de distérbios metabàlicos-relacionados destes | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| ECSP088966A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| BR0308133A (pt) | Forma polimórfica cristalina de cloridrato de irinotecan | |
| BR0208405A (pt) | Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças | |
| BRPI0507120A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização | |
| BR0315346A (pt) | Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, formulação farmacêutica e utilização de inibidor de re-apreensão de norepinefrina em combinação com antagonista de 5-h2a | |
| BR112012020060B8 (pt) | uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência | |
| ATE473961T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| BRPI0606502A2 (pt) | compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento ou prevenção de doenças que são associadas com a modulação de receptores h3; método para o tratamento ou prevenção de obesidade em um ser humano ou animal; método de tratamento ou prevenção de diabetes tipo ii em um ser humano ou animal e usos de compostos | |
| BRPI0809873A2 (pt) | "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento" | |
| BR0105787A (pt) | Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico | |
| BRPI0414494A (pt) | compostos, composições farmacêuticas, e, uso de um composto | |
| ATE523488T1 (de) | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: ALMIRALL AG (CH) Free format text: ALTERADO DE: ALMIRALL PRODESFARMA AG |
|
| B25A | Requested transfer of rights approved |
Owner name: LABORATORIOS ALMIRALL, S.A. (ES) Free format text: TRANSFERIDO DE: ALMIRALL AG |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 7A. E 8A. ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A E 8A ANUIDADES. |